JP2016504992A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016504992A5 JP2016504992A5 JP2015548639A JP2015548639A JP2016504992A5 JP 2016504992 A5 JP2016504992 A5 JP 2016504992A5 JP 2015548639 A JP2015548639 A JP 2015548639A JP 2015548639 A JP2015548639 A JP 2015548639A JP 2016504992 A5 JP2016504992 A5 JP 2016504992A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- group
- ethanol
- methylamino
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- GIGVAWWBRRBBAJ-UHFFFAOYSA-N 2-[4-[3-(methylamino)-1-phenylpropoxy]phenyl]ethanol Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(CCO)C=C1 GIGVAWWBRRBBAJ-UHFFFAOYSA-N 0.000 claims 3
- 208000012239 Developmental disease Diseases 0.000 claims 3
- 208000012902 Nervous system disease Diseases 0.000 claims 3
- 230000003542 behavioural effect Effects 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 208000020016 psychiatric disease Diseases 0.000 claims 3
- 102100021257 Beta-secretase 1 Human genes 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- GBWFSDNIWQRAFG-UHFFFAOYSA-N 1-[2-[4-(2-hydroxyethyl)phenoxy]ethyl]pyrrolidin-2-one Chemical compound C1=CC(CCO)=CC=C1OCCN1C(=O)CCC1 GBWFSDNIWQRAFG-UHFFFAOYSA-N 0.000 claims 1
- DSCFFEYYQKSRSV-UHFFFAOYSA-N 1L-O1-methyl-muco-inositol Natural products COC1C(O)C(O)C(O)C(O)C1O DSCFFEYYQKSRSV-UHFFFAOYSA-N 0.000 claims 1
- -1 2- [4- [3- (methylamino) -1-phenylpropoxy] phenyl] ethanol (R) -lipoic acid salt Chemical class 0.000 claims 1
- UYYDGUWIYGERMB-UHFFFAOYSA-N 2-[4-(morpholin-2-ylmethoxy)phenyl]ethanol;hydrochloride Chemical compound Cl.C1=CC(CCO)=CC=C1OCC1OCCNC1 UYYDGUWIYGERMB-UHFFFAOYSA-N 0.000 claims 1
- YQSGMMPWDSHWDJ-GMUIIQOCSA-N 2-[4-[(1r)-3-(methylamino)-1-phenylpropoxy]phenyl]ethanol;hydrochloride Chemical compound Cl.O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(CCO)C=C1 YQSGMMPWDSHWDJ-GMUIIQOCSA-N 0.000 claims 1
- OAEMFLGMZNYRKM-OAHLLOKOSA-N 2-[4-[(1r)-3-(methylamino)-1-thiophen-2-ylpropoxy]phenyl]ethanol Chemical compound O([C@H](CCNC)C=1SC=CC=1)C1=CC=C(CCO)C=C1 OAEMFLGMZNYRKM-OAHLLOKOSA-N 0.000 claims 1
- YQSGMMPWDSHWDJ-FERBBOLQSA-N 2-[4-[(1s)-3-(methylamino)-1-phenylpropoxy]phenyl]ethanol;hydrochloride Chemical compound Cl.O([C@@H](CCNC)C=1C=CC=CC=1)C1=CC=C(CCO)C=C1 YQSGMMPWDSHWDJ-FERBBOLQSA-N 0.000 claims 1
- OAEMFLGMZNYRKM-HNNXBMFYSA-N 2-[4-[(1s)-3-(methylamino)-1-thiophen-2-ylpropoxy]phenyl]ethanol Chemical compound O([C@@H](CCNC)C=1SC=CC=1)C1=CC=C(CCO)C=C1 OAEMFLGMZNYRKM-HNNXBMFYSA-N 0.000 claims 1
- YQSGMMPWDSHWDJ-UHFFFAOYSA-N 2-[4-[3-(methylamino)-1-phenylpropoxy]phenyl]ethanol;hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(CCO)C=C1 YQSGMMPWDSHWDJ-UHFFFAOYSA-N 0.000 claims 1
- CKAFHCHOEVHXAE-PXNSSMCTSA-N 2-[4-[[(3s,4r)-4-(4-fluorophenyl)piperidin-3-yl]methoxy]phenyl]ethanol Chemical compound C1=CC(CCO)=CC=C1OC[C@H]1[C@H](C=2C=CC(F)=CC=2)CCNC1 CKAFHCHOEVHXAE-PXNSSMCTSA-N 0.000 claims 1
- BAGMPXLPHMULTJ-UHFFFAOYSA-N 2-[4-[morpholin-2-yl(phenyl)methoxy]phenyl]ethanol Chemical compound C1=CC(CCO)=CC=C1OC(C=1C=CC=CC=1)C1OCCNC1 BAGMPXLPHMULTJ-UHFFFAOYSA-N 0.000 claims 1
- JJZFWROHYSMCMU-UHFFFAOYSA-N 3-(benzenesulfonyl)-8-piperazin-1-ylquinoline Chemical compound C=1N=C2C(N3CCNCC3)=CC=CC2=CC=1S(=O)(=O)C1=CC=CC=C1 JJZFWROHYSMCMU-UHFFFAOYSA-N 0.000 claims 1
- MZRKHUUDDHJVHS-MOKVOYLWSA-N 3-ethyl-n-[(5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-2-oxobenzimidazole-1-carboxamide Chemical compound C1C(N2C)CC[C@H]2CC1NC(=O)N1C2=CC=CC=C2N(CC)C1=O MZRKHUUDDHJVHS-MOKVOYLWSA-N 0.000 claims 1
- VCQZCDSEWSFTPO-SJORKVTESA-N 4-[(1s,2s)-2-(4-cyclobutylpiperazine-1-carbonyl)cyclopropyl]benzamide Chemical compound C1=CC(C(=O)N)=CC=C1[C@@H]1[C@@H](C(=O)N2CCN(CC2)C2CCC2)C1 VCQZCDSEWSFTPO-SJORKVTESA-N 0.000 claims 1
- KAKWRMDVZQPECF-UHFFFAOYSA-N 4-[4-[3-(methylamino)-1-phenylpropoxy]phenyl]butan-1-ol;hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(CCCCO)C=C1 KAKWRMDVZQPECF-UHFFFAOYSA-N 0.000 claims 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000009575 Angelman syndrome Diseases 0.000 claims 1
- 208000036640 Asperger disease Diseases 0.000 claims 1
- 201000006062 Asperger syndrome Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 101710150192 Beta-secretase 1 Proteins 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- OFVNMCFEMDCZKP-PWKISDLSSA-N CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)CCOC3=C(C(=O)O[C@@H]3[C@H](CO)O)O Chemical compound CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)CCOC3=C(C(=O)O[C@@H]3[C@H](CO)O)O OFVNMCFEMDCZKP-PWKISDLSSA-N 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- VJXUJFAZXQOXMJ-UHFFFAOYSA-N D-1-O-Methyl-muco-inositol Natural products CC12C(OC)(C)OC(C)(C)C2CC(=O)C(C23OC2C(=O)O2)(C)C1CCC3(C)C2C=1C=COC=1 VJXUJFAZXQOXMJ-UHFFFAOYSA-N 0.000 claims 1
- DSCFFEYYQKSRSV-KLJZZCKASA-N D-pinitol Chemical compound CO[C@@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@H]1O DSCFFEYYQKSRSV-KLJZZCKASA-N 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000024412 Friedreich ataxia Diseases 0.000 claims 1
- 102000004300 GABA-A Receptors Human genes 0.000 claims 1
- 108090000839 GABA-A Receptors Proteins 0.000 claims 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims 1
- 229940125373 Gamma-Secretase Inhibitor Drugs 0.000 claims 1
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 102000010909 Monoamine Oxidase Human genes 0.000 claims 1
- 108010062431 Monoamine oxidase Proteins 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 1
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims 1
- PBHFNBQPZCRWQP-AZUAARDMSA-N [(3aS,8bR)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-phenylcarbamate Chemical compound CN([C@H]1[C@](C2=C3)(C)CCN1C)C2=CC=C3OC(=O)NC1=CC=CC=C1 PBHFNBQPZCRWQP-AZUAARDMSA-N 0.000 claims 1
- WCLRTWSSCPEHJI-UHFFFAOYSA-N [4-[3-(methylamino)-1-phenylpropoxy]phenyl]methanol;hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(CO)C=C1 WCLRTWSSCPEHJI-UHFFFAOYSA-N 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000001896 anti-amyloidogenic effect Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- UTMVACIBQLDZLP-UHFFFAOYSA-N crisdesalazine Chemical compound C1=C(O)C(C(=O)O)=CC(NCCC=2C=CC(=CC=2)C(F)(F)F)=C1 UTMVACIBQLDZLP-UHFFFAOYSA-N 0.000 claims 1
- 229960003530 donepezil Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940030275 epigallocatechin gallate Drugs 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- OPQRBXUBWHDHPQ-UHFFFAOYSA-N etazolate Chemical compound CCOC(=O)C1=CN=C2N(CC)N=CC2=C1NN=C(C)C OPQRBXUBWHDHPQ-UHFFFAOYSA-N 0.000 claims 1
- 229950009329 etazolate Drugs 0.000 claims 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 claims 1
- 229940114123 ferulate Drugs 0.000 claims 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims 1
- 229960003980 galantamine Drugs 0.000 claims 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims 1
- 239000003540 gamma secretase inhibitor Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 claims 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 claims 1
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 230000028252 learning or memory Effects 0.000 claims 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 1
- 229960004640 memantine Drugs 0.000 claims 1
- 239000000359 muscarinic M1 receptor agonist Substances 0.000 claims 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 claims 1
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 claims 1
- 229960000245 rasagiline Drugs 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 229940016667 resveratrol Drugs 0.000 claims 1
- 235000021283 resveratrol Nutrition 0.000 claims 1
- 229960004136 rivastigmine Drugs 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims 1
- 229940102566 valproate Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12382527.5A EP2745876A1 (en) | 2012-12-21 | 2012-12-21 | Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives |
| EP12382527.5 | 2012-12-21 | ||
| PCT/EP2013/077731 WO2014096377A1 (en) | 2012-12-21 | 2013-12-20 | Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016504992A JP2016504992A (ja) | 2016-02-18 |
| JP2016504992A5 true JP2016504992A5 (enExample) | 2017-01-05 |
| JP6302929B2 JP6302929B2 (ja) | 2018-03-28 |
Family
ID=47559245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015548639A Active JP6302929B2 (ja) | 2012-12-21 | 2013-12-20 | ヒドロキシ脂肪族置換フェニルアミノアルキルエーテル誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9624158B2 (enExample) |
| EP (2) | EP2745876A1 (enExample) |
| JP (1) | JP6302929B2 (enExample) |
| AU (1) | AU2013366502B2 (enExample) |
| CA (1) | CA2895592C (enExample) |
| DK (1) | DK2945702T3 (enExample) |
| ES (1) | ES2621960T3 (enExample) |
| HR (1) | HRP20170539T1 (enExample) |
| HU (1) | HUE032461T2 (enExample) |
| PT (1) | PT2945702T (enExample) |
| WO (1) | WO2014096377A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2647377A1 (en) | 2012-04-06 | 2013-10-09 | Sanofi | Use of an h3 receptor antagonist for the treatment of alzheimer's disease |
| CN105764510A (zh) * | 2013-09-09 | 2016-07-13 | 赛诺菲 | H3受体拮抗剂与胆碱酶抑制剂组合用于阿尔茨海默氏病治疗中的用途 |
| CN106349211B (zh) * | 2016-08-26 | 2020-10-16 | 江苏恩华药业股份有限公司 | 2-甲基-3-芳氧基-3-杂芳基丙胺类化合物及应用 |
| KR101864085B1 (ko) * | 2017-09-22 | 2018-06-01 | 동아대학교 산학협력단 | 발프로산 유도체, 이의 제조방법 및 이를 포함하는 항경련제 |
| EP3697754A1 (en) * | 2017-10-16 | 2020-08-26 | Esteve Pharmaceuticals, S.A. | Propanamine derivatives for treating pain and pain related conditions |
| US11629154B2 (en) | 2018-04-27 | 2023-04-18 | Shionogi & Co., Ltd. | Tetrahydropyranooxazine derivatives having selective BACE1 inhibitory activity |
| EP3838899A4 (en) | 2018-08-17 | 2022-02-16 | Shanghai Leado Pharmatech Co. Ltd. | 3-aryloxyl-3-five-membered heteroaryl propylamine compound and use thereof |
| US12570643B2 (en) | 2019-05-16 | 2026-03-10 | Shanghai Leado Pharmatech Co. Ltd. | 3-aryloxy-3-five-membered heteroaryl propylamine compound, and crystal form and use thereof |
| WO2020259787A1 (en) * | 2019-06-28 | 2020-12-30 | University Of Copenhagen | Treatment of cns disorders with sleep disturbances |
| KR20250030127A (ko) * | 2023-08-24 | 2025-03-05 | 경희대학교 산학협력단 | 피니톨을 함유한 감각 운동 관문 장애 예방 또는 치료용 조성물 |
| EP4678628A1 (en) * | 2024-07-10 | 2026-01-14 | Connecta Theapeutics, S.L. | Compounds and compositions for the treatment of nervous system disorders |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002076925A2 (en) * | 2001-03-23 | 2002-10-03 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
| WO2003082259A1 (en) * | 2002-04-03 | 2003-10-09 | Puleva Biotech, S.A. | Natural phenolic products and derivatives thereof for protection against neurodegenerative diseases |
| GB0409744D0 (en) | 2004-04-30 | 2004-06-09 | Pfizer Ltd | Novel compounds |
| AU2005238296A1 (en) * | 2004-04-30 | 2005-11-10 | Warner-Lambert Company Llc | Substituted morpholine compounds for the treatment of central nervous system disorders |
| SE526297C2 (sv) | 2004-07-27 | 2005-08-16 | Jan Norrman | Kopplingsstycke innefattande en ledare med flertal trådar vilka är fördelade kring en deformerbar kropps ytteromkrets |
| GB0505509D0 (en) * | 2005-03-17 | 2005-04-27 | Ic Innovations Ltd | Compounds |
| ATE527262T1 (de) | 2006-01-25 | 2011-10-15 | Sanofi Sa | Neue tomaymycin derivate enhaltende zytotoxische mittel |
| CN100528832C (zh) * | 2007-02-08 | 2009-08-19 | 刘宏民 | 左旋盐酸倍他洛尔合成工艺 |
| US20120004310A1 (en) * | 2010-05-28 | 2012-01-05 | Longo Frank M | Non-peptide bdnf neurotrophin mimetics |
| EP2664616A1 (en) * | 2012-05-15 | 2013-11-20 | Vivalis | Hydantoin and thiohydantoin derivatives as antiviral drugs |
-
2012
- 2012-12-21 EP EP12382527.5A patent/EP2745876A1/en not_active Withdrawn
-
2013
- 2013-12-20 HU HUE13811569A patent/HUE032461T2/en unknown
- 2013-12-20 WO PCT/EP2013/077731 patent/WO2014096377A1/en not_active Ceased
- 2013-12-20 EP EP13811569.6A patent/EP2945702B1/en active Active
- 2013-12-20 DK DK13811569.6T patent/DK2945702T3/en active
- 2013-12-20 HR HRP20170539TT patent/HRP20170539T1/hr unknown
- 2013-12-20 JP JP2015548639A patent/JP6302929B2/ja active Active
- 2013-12-20 US US14/654,661 patent/US9624158B2/en active Active
- 2013-12-20 CA CA2895592A patent/CA2895592C/en active Active
- 2013-12-20 AU AU2013366502A patent/AU2013366502B2/en active Active
- 2013-12-20 PT PT138115696T patent/PT2945702T/pt unknown
- 2013-12-20 ES ES13811569.6T patent/ES2621960T3/es active Active
-
2017
- 2017-04-17 US US15/489,186 patent/US9980928B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170539T1 (hr) | Hidroksialifatski supstituirani derivati fenilaminoalkil-etera | |
| RU2016131875A (ru) | Производные n-фениллактама, способные стимулировать нейрогенез, и их применение при лечении заболеваний нервной системы | |
| JP2015509535A5 (enExample) | ||
| RU2017132673A (ru) | Производные собетирома | |
| JP2014051526A5 (enExample) | ||
| JP2013523733A5 (enExample) | ||
| JP2023508469A5 (enExample) | ||
| JP2015501799A5 (enExample) | ||
| JP2014526469A5 (enExample) | ||
| JP2015509110A5 (enExample) | ||
| JP2012530779A5 (enExample) | ||
| JP2015516420A5 (enExample) | ||
| JP2016529319A5 (enExample) | ||
| JP2014505017A5 (enExample) | ||
| JP2016529315A5 (enExample) | ||
| JP2014062126A5 (enExample) | ||
| JP2016514159A5 (enExample) | ||
| RU2015112914A (ru) | Бензимидазолы в качестве активных агентов для центральной нервной системы | |
| RU97102362A (ru) | Нейрозащитные производные 3-(пиперидинил-1)-хроман-4,7-диола и 1-(4- гидроксифенил)-2-(пиперидинил-1)-алканола | |
| JP2013522368A5 (enExample) | ||
| JP2013506674A5 (enExample) | ||
| JP2016537338A5 (enExample) | ||
| RU2016104890A (ru) | Производные 1,7-нафтиридина | |
| RU2011102523A (ru) | Новые производные тетраметил-замещенного пиперидина и их применение в качестве ингибиторов обратного захвата моноаминовых нейромедиаторов | |
| RU2015148927A (ru) | Производные изохинолина, стимулирующие нейрогенез |